DOCSLIB.ORG

Report : RBT-2015-R Interchange MMIS Run Date: 05

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

Report : RBT-2015-R interChange MMIS Run Date: 05/25/2010 Process : RBTJR330 MEDICAID MANAGEMENT INFORMATION SYSTEM Run Time: 17:08:55 Location: RBT2015R DRUG REBATE PARTICIPATION BY LABELER CODE Page: 62 SAGA LABELER REBATE REBATE CODE LABELER NAME EFFECTIVE DATE TERMINATION DATE 00002 ELI LILLY AND COMPANY 01/01/1991 12/31/2299 00003 E.R. SQUIBB & SONS, INC. 01/01/1991 12/31/2299 00004 HOFFMANN-LA ROCHE 01/01/1991 12/31/2299 00005 LEDERLE LABORATORIES 01/01/1991 12/31/2299 00006 MERCK & CO., INC. 01/01/1991 12/31/2299 00007 GLAXOSMITHKLINE 01/01/2009 12/31/2299 00008 WYETH LABORATORIES 01/01/1991 12/31/2299 00009 PFIZER, INC 01/01/1991 12/31/2299 00011 BECTON DICKINSON MICROBIOLOGY SYSTEMS 10/01/1991 06/30/1998 00013 PFIZER, INC. 01/01/1991 12/31/2299 00014 PHARMACIA CORPORATION 01/01/1991 12/31/2000 00015 MEAD JOHNSON AND COMPANY 01/01/1991 12/31/2299 00016 PHARMACIA CORPORATION 01/01/1991 12/31/2002 00021 REED AND CARNRICK DIV OF BLOCK DRUG 10/01/1996 12/31/1996 00023 ALLERGAN INC 01/01/1991 12/31/2299 00024 SANOFI-AVENTIS, US LLC 01/01/1991 12/31/2299 00025 PFIZER, INC. 01/01/1991 12/31/2299 00026 BAYER CORPORATION PHARMACEUTICAL DIV. 01/01/1991 12/31/2299 00028 NOVARTIS 01/01/1991 12/31/2299 00029 GLAXOSMITHKLINE 01/01/2009 12/31/2299 00031 A. H. ROBINS 01/01/1991 12/31/2299 00032 SOLVAY PHARMACEUTICALS, INC. 01/01/1991 12/31/2299 00033 SYNTEX LABORATORIES, INC. 01/01/1991 09/30/2002 00034 PURDUE FREDERICK COMPANY 01/01/1991 12/31/2008 00037 MEDA PHARMACEUTICALS, INC. 01/01/1991 12/31/2299 00038 STUART PHARMACEUTICALS 01/01/1991 06/30/2001 00039 SANOFI-AVENTIS, US LLC 01/01/1991 12/31/2299 00043 NOVARTIS CONSUMER HEALTH, INC. 01/01/1991 09/30/2005 00044 KNOLL PHARMACEUTICAL COMPANY 01/01/1991 03/31/2007 00045 ORTHO-MCNEIL-JANSSEN PHARMECEUTICAL, IN 01/01/1991 12/31/2299 00046 AYERST LABORATORIES 01/01/1991 12/31/2299 00047 WARNER CHILCOTT LABORATORIES 01/01/1991 12/31/2004 00048 KNOLL PHARMACEUTICAL COMPANY 01/01/1991 09/30/2006 00049 PFIZER, INC 01/01/1991 12/31/2299 00051 UNIMED PHARMACEUTICALS, INC 10/01/1997 12/31/2299 00052 ORGANON USA INC. 01/01/1991 12/31/2006 00053 CSL BEHRING 01/01/1991 12/31/2299 00054 ROXANE LABORATORIES, INC. 01/01/1991 12/31/2299 00056 DUPONT PHARMACEUTICALS 01/01/2008 12/31/2299 00058 NOVARTIS OPHTHALMICS, INC. 01/01/1991 06/30/2004 00060 DUPONT PHARMACEUTICALS 01/01/1991 06/30/2000 00062 ORTHO-MCNEIL JANSSEN PHARMACEUTICALS 01/01/1991 12/31/2299 00064 HEALTHPOINT, LTD. 07/01/1995 12/31/2299 00065 ALCON LABORATORIES, INC. 01/01/1991 12/31/2299 00066 AVENTIS PHARMACEUTICALS, INC. 01/01/1991 12/31/2299 00067 NOVARTIS CONSUMER HEALTH, INC. 01/01/1991 03/31/2009 Report : RBT-2015-R interChange MMIS Run Date: 05/25/2010 Process : RBTJR330 MEDICAID MANAGEMENT INFORMATION SYSTEM Run Time: 17:08:55 Location: RBT2015R DRUG REBATE PARTICIPATION BY LABELER CODE Page: 63 SAGA LABELER REBATE REBATE CODE LABELER NAME EFFECTIVE DATE TERMINATION DATE 00068 AVENTIS PHARMACEUTICALS 01/01/1991 12/31/2299 00069 PFIZER, INC 01/01/1991 12/31/2299 00070 AVENTIS PHARMACEUTICALS 07/01/1993 12/31/2005 00071 PFIZER, INC 01/01/1991 12/31/2299 00072 WESTWOOD-SQUIBB PHARMACEUTICALS 01/01/1991 03/31/2007 00074 ABBOTT LABORATORIES 01/01/1991 12/31/2299 00075 AVENTIS PHARMACEUTICALS, INC. 01/01/1991 12/31/2299 00076 STAR PHARMACEUTICALS, INC. 01/01/1991 12/31/2008 00078 NOVARTIS 01/01/1991 12/31/2299 00081 GLAXOSMITHKLINE 01/01/1991 12/31/2002 00083 NOVARTIS 01/01/1991 12/31/2299 00085 SCHERING CORPORATION 01/01/1991 12/31/2006 00086 ELAN PHARMACEUTICALS, INC./CARNRICK LAB 01/01/1991 12/31/2007 00087 BRISTOL-MYERS SQUIBB COMPANY 01/01/1991 12/31/2299 00088 AVENTIS PHARMACEUTICALS 01/01/1991 12/31/2299 00089 3M PHARMACEUTICALS 01/01/1991 12/31/2299 00091 SCHWARZ PHARMA, LLC 01/01/1991 12/31/2299 00093 TEVA PHARMACEUTICALS USA, INC. 01/01/1991 12/31/2299 00095 ECR PHARMACEUTICALS 10/01/1991 12/31/2299 00096 PERSON & COVEY, INC. 04/01/1999 07/30/2009 00108 GLAXOSMITHKLINE 01/01/1991 12/31/2005 00113 L. PERRIGO COMPANY 02/01/2008 12/31/2299 00115 GLOBAL PHARMACEUTICAL CORPORATION 10/01/2009 12/31/2299 00116 XTTRIUM LABORATORIES, INC. 08/17/2001 06/30/2009 00118 BAYER CORPORATION ALLERGY PRODUCTS 01/01/1991 09/30/2003 00121 PHARMACEUTICAL ASSOCIATES, INC. 01/01/1991 12/31/2299 00126 COLGATE ORAL PHARMACEUTICALS, INC. 01/01/1991 12/31/2299 00131 SCHWARZ PHARMA LLC 01/01/1991 12/31/2299 00132 C B FLEET COMPANY INC 01/01/1991 06/30/2009 00135 GLAXOSMITHKLINE 01/01/1995 12/31/2299 00143 WEST-WARD PHARMACEUTICAL CORP 01/01/1991 12/31/2299 00144 SUPERIOR PHARMACEUTICAL COMPANY 04/01/1995 03/31/2002 00145 STIEFEL LABORATORIES, INC, 01/01/1991 12/31/2299 00147 CAMALL COMPANY 01/01/1991 09/30/2001 00149 PROCTER & GAMBLE PHARMACEUTICALS, INC. 01/01/1991 12/31/2299 00152 THE GRAY PHARMACEUTICAL COMPANY 01/01/1991 09/30/2003 00161 BAYER CORPORATION BIOLOGICAL PRODUCTS 01/01/1991 09/30/2000 00165 BLAINE COMPANY 01/01/1992 06/30/2009 00168 E FOUGERA AND CO. 01/01/1991 12/31/2299 00169 NOVO NORDISK, INC. 01/01/1991 12/31/2299 00172 IVAX PHARMACEUTICALS, INC. 01/01/1991 12/31/2299 00173 GLAXOSMITHKLINE 01/01/2009 12/31/2299 00178 MISSION PHARMACAL COMPANY 01/01/1991 06/30/2009 00182 GOLDLINE LABORATORIES, INC. 01/01/1991 12/31/2299 00185 EON LABS, INC. 01/01/1991 12/31/2299 00186 ASTRAZENECA LP 10/01/2008 12/31/2299 Report : RBT-2015-R interChange MMIS Run Date: 05/25/2010 Process : RBTJR330 MEDICAID MANAGEMENT INFORMATION SYSTEM Run Time: 17:08:55 Location: RBT2015R DRUG REBATE PARTICIPATION BY LABELER CODE Page: 64 SAGA LABELER REBATE REBATE CODE LABELER NAME EFFECTIVE DATE TERMINATION DATE 00187 VALEANT PHARMACEUTICALS NORTH AMERICA 01/01/1991 06/02/2009 00192 BAYER CORPORATION BIOLOGICAL PRODUCTS 10/01/1994 09/30/2003 00205 LEDERLE PARENTERALS 01/01/1991 06/30/2007 00206 LEDERLE PIPERACILLIN 01/01/1991 12/31/2299 00209 MARSAM PHARMACEUTICALS INC. 10/01/1994 03/31/2004 00214 GLAXOSMITHKLINE 12/03/2001 03/31/2007 00217 DUNHALL PHARMACEUTICALS 01/01/2000 09/30/2001 00224 KONSYL PHARMACEUTICALS, INC. 01/01/1992 06/30/2009 00225 B. F. ASCHER AND COMPANY, INC. 01/01/1991 07/30/2009 00228 ACTAVIS ELIZABETH LLC 01/01/1991 12/31/2299 00245 UPSHER-SMITH LABORATORIES, INC. 01/01/1991 12/31/2299 00249 GERIATRIC PHARMACEUTICAL CORP. 01/01/1991 09/30/1998 00254 VINTAGE PHARMACEUTICALS, INC. 04/01/1993 03/31/2008 00256 FLEMING AND COMPANY 10/01/1991 06/30/2009 00258 INWOOD LABORATORIES INC 01/01/1991 12/31/2299 00259 MERZ PHARMACEUTICALS 01/01/1991 12/31/2299 00263 RYSTAN COMPANY, INC. 10/01/1994 03/31/2002 00264 B. BRAUN MEDICAL INC. 01/01/1991 09/30/2009 00268 CENTER LABORATORIES 01/01/1991 09/30/2002 00274 SCHERER LABORATORIES INC 01/01/1991 12/31/1999 00276 MISEMER PHARMACEUTICAL, INC. 07/10/2006 06/30/2009 00277 LASER PHARMACEUTICALS, LLC 01/01/1991 09/30/2009 00281 SAVAGE LABORATORIES 01/01/1991 12/31/2299 00288 FLUORITAB CORPORATION 10/01/1991 06/30/2009 00299 GALDERMA LABORATORIES, L.P. 01/01/1991 08/31/2002 00300 TAP PHARMACEUTICALS INC 01/01/1991 12/31/2299 00303 BAUSCH & LOMB PHARMACEUTICALS, INC. 01/01/1991 12/31/1997 00304 H.D. SMITH WHOLESALE DRUG COMPANY 01/01/1991 06/30/2007 00310 ASTRAZENECA LP 10/01/2008 12/31/2299 00314 HYREX PHARMACEUTICALS 01/01/1991 03/31/2003 00327 GUARDIAN LABS DIV UNITED-GUARDIAN INC 01/01/1991 12/31/2299 00332 BIOCRAFT LABORATORIES, INC. 01/01/1991 12/31/2006 00338 BAXTER HEALTHCARE CORPORATION 01/01/1991 09/30/2009 00349 PARMED PHARMACEUTICALS INC. 01/01/1991 09/30/2002 00353 AMERICAN PHARMACAL, INC. 01/01/1995 12/31/1999 00364 WATSON PHARMA, INC. 01/01/1991 12/31/2008 00372 SCOT-TUSSIN PHARMACAL CO., INC. 04/01/1992 06/30/2004 00378 MYLAN PHARMACEUTICALS, INC. 01/01/1991 12/31/2299 00386 GEBAUER COMPANY 01/01/1991 06/30/2000 00392 CRANDALL ASSOCIATE 01/01/1991 06/30/1999 00402 STERIS LABORATORIES, INC. 01/01/1991 06/30/2005 00405 ALIGEN INDEPENDENT LABORATORIES, INC. 01/01/1991 09/30/1997 00406 MALLINCKRODT INC. 10/01/1991 12/31/2299 00409 HOSPIRA, INC. 10/28/2004 06/30/2009 00414 PERRIGO PHARMACEUTICALS 04/01/1994 12/31/2299 00417 HALL LABORATORIES, INCORPORATED 10/01/1992 03/31/1998 Report : RBT-2015-R interChange MMIS Run Date: 05/25/2010 Process : RBTJR330 MEDICAID MANAGEMENT INFORMATION SYSTEM Run Time: 17:08:55 Location: RBT2015R DRUG REBATE PARTICIPATION BY LABELER CODE Page: 65 SAGA LABELER REBATE REBATE CODE LABELER NAME EFFECTIVE DATE TERMINATION DATE 00418 PASADENA RESEARCH LABORATORIES, INC. 10/01/1996 09/30/1997 00421 NOVAVAX, INC. (FORMERLY FIELDING) 01/01/1991 12/31/2299 00426 MORTON GROVE PHARMACEUTICALS, INC. 01/01/1994 06/30/1999 00430 WARNER CHILCOTT LABORATORIES 01/01/1998 12/31/2299 00451 MURO ASTA MEDICA 01/01/1991 03/31/2004 00456 FOREST LABORATORIES, INC. 01/01/1991 12/31/2299 00462 PHARMADERM 02/01/2008 12/31/2299 00463 C O TRUXTON INC 10/01/2003 09/30/2004 00469 ASTELLAS PHARMA US, INC.
Recommended publications
  • BIO-2005-MK-ONLINE (Page 1)

    BIO-2005-MK-ONLINE (Page 1)

    THE SCIENCE. THE BUSINESS. THE WORLD OF BIOPHARMACEUTICALS. 2005 MEDIA PLANNER www.biopharminternational.com THE PRINT-BASED MARKETING Display Advertising BIOPHARM The foundation of any b-to-b marketing program, print advertising allows you to BRAND touch 29,200 BPA-qualified subscribers* with your brand or product message. BioPharm International’s Build your marketing plan around the message portfolio of products allows conveyed in your print ad and utilize other channels you to reach our highly to further reinforce your message. desirable audience through multiple marketing channels. Custom Publishing Work with us to write and design a custom white paper or article Studies show integrated published as an advertorial in the pages of BioPharm. marketing is the key to successfully delivering your Insert A unique way to deliver white papers, brochures or any other collateral message to today’s buyer. material to our readers. Reinforce your message to the most important audience Polybag in your market—ask your Talk about premium placement! Send your printed piece as a ride-along advertising sales manager and readers will get the message as soon as the issue hits their desk. to design an integrated program Direct Mail utilizing the channels that best Planning a direct mail campaign to reinforce your ad message? meet your marketing objectives. Rent our list to ensure your marketing material reaches your most important audience. Post-It Note A truly unique way to send your message to our readers, Post-It Notes serve as front cover reminders about your brand. Use Post-Its to call out your ads in the issue or run 6 or 12 Post-It Notes for a truly unique campaign.
  • Breaking Eroom's

    Breaking Eroom's

    Breaking Eroom’s Law Michael S. Ringel, Jack W. Scannell, Mathias Baedeker and Ulrik Schulze https://doi.org/10.1038/d41573-020-00059-3 Supplementary Box 1 | Data and analysis Breaking Eroom’s Law The count and value of NMEs relative to R&D spend comes from BCG’s New Therapeutic Drug (NTD) Database, which is also the source of BCG’s annual publication in Nat. Rev. Drug. Discov. showing trends in count and value over time.1 FDA approvals are from FDA’s Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER),2 peak sales estimates are from EvaluatePharma®,3 and R&D spend data are from BCG Value Science, inflation-adjusted using the standard global GDP-based inflator from the Economist Intelligence Unit.4 For additional details on methodology, see Schulze, Baedeker, Chen and Greber.5 Eroom’s Law is linear on a log scale through 2010, with an average increase approximately 12% per annum, or a halving of productivity approximately every seven years. If this holds true even after 2010, we would see a continuation of the linear development of the number of drugs approved per billion US$ R&D spending when using a logarithmic scale. To demonstrate that the deviation from regression after 2010 is statistically relevant we assumed the following: 1) Eroom's law is true up to 2010. 2) Eroom's law is not true between 2010 and 2018. To confirm our assumptions, we used a log-linear regression to describe the number of new molecular entities (NMEs) approved by the US FDA per billion US$ R&D spending from 1950–2010.
  • 05/01/02 Louisiana Medicaid Management

    05/01/02 Louisiana Medicaid Management

    APPENDIX C 05/01/02 LOUISIANA MEDICAID MANAGEMENT INFORMATION SYSTEM PAGE 1 DEPT OF HEALTH AND HOSPITALS - BUREAU OF HEALTH SERVICES FINANCING LOUISIANA MEDICAID PHARMACY BENEFITS MANAGEMENT UNIT ONLY THESE COMPANIES PRODUCTS ARE COVERED AND ONLY THOSE DOSAGE FORMS LISTED IN APPENDIX A. MEDICAID DRUG FEDERAL REBATE PARTICIPATING PHARMACEUTICAL COMPANIES LABELER PHARMACEUTICAL COMPANY EFFECTIVE END DATE CODE DATE 00002 ELI LILLY & CO 04/01/91 00003 E.R.SQUIBB & SONS,INC 04/01/91 00004 HOFFMAN-LA ROCHE,INC 04/01/91 00005 LEDERLE LABORATORIES AMERICAN CYANAMID 04/01/91 00006 MERCK SHARP & DOHME 04/01/91 00007 SMITHKLINE BEECHAM CORPORATION 04/01/91 00008 WYETH LABORATORIES 04/01/91 00009 THE UPJOHN COMPANY 04/01/91 00011 BECTON DICKINSON MICROBIOLOGY SYSTEMS 10/01/91 07/01/98 00013 ADRIA LABORATORIES DIV.OF ERBAMONT,INC 04/01/91 00014 G.D.SEARLE & CO 04/01/91 01/01/01 00015 MEAD JOHNSON & COMPANY 04/01/91 00016 KABI PHARMACIA 04/01/91 00021 REED & CARNRICK 10/01/96 01/01/97 00023 ALLERGAN,INC 04/01/91 00024 WINTHROP PHARMACEUTICALS 04/01/91 00025 G.D.SEARLE & CO 04/01/91 00026 MILES INC.,PHARMACEUTICAL DIVISION 04/01/91 00028 GEIGY PHARMACEUTICALS 04/01/91 00029 SMITHKLINE BEECHAM CORPORATION 04/01/91 00031 ROBINS,A.H. 04/01/91 00032 SOLVAY PHARMACEUTICALS 04/01/91 00033 SYNTEX 04/01/91 00034 THE PURDUE FREDERICK COMPANY 04/01/91 00037 CARTER-WALLACE,INC 04/01/91 00038 STUART PHARMACEUTICALS,ICI AMERICAS INC 04/01/91 07/01/01 00039 HOECHST-ROUSSEL PHARMACEUTICALS INC 04/01/91 00043 SANDOZ CONSUMER CORPORATION 04/01/91 00044 KNOLL PHARMACEUTICALS
  • Pfizer's Bourla

    Pfizer's Bourla

    No. 3985 December 13, 2019 line success and business development. “In the next two years, we need to see how the pipeline is delivering,” he said. Bourla has been outspoken that when it comes to business development, he doesn’t see a mega-merger on the hori- zon. Instead, he said he is looking to bring in mid-stage clinical development assets to complement the internal pipeline. It sounds like investors can expect the company to be active on the business development front within those guard- rails. “I want to double it,” he said of the pipeline, which includes 92 projects right now. “And, we are going to double it by bringing in a lot of innovation to comple- ment what we distribute.” The company is focusing business de- velopment on six core therapeutic areas Pfizer’s Bourla: “I Think We Forgot as well, but Bourla indicated the company will be actively building out those areas both through internal investment and What It Looks Like To Grow” external collaboration. “We’re going to be JESSICA MERRILL [email protected] active because Pfizer is a very big plane and it cannot fly with one engine,” he said. fizer Inc. CEO Albert Bourla took in July it will merge the Upjohn business Bourla highlighted Pfizer’s recent acqui- over the top leadership spot from with Mylan NV to form a new generic drug sition of the cancer specialist Array Bio- PIan Read a year ago, but has quickly company to be called Viatris GMBH. Pharma for $11.4bn as an example of the executed on big changes poised to make The resulting Pfizer will be significantly kinds of deals the company will be pursu- Pfizer significantly smaller and faster smaller, with a 2020 annual revenue base ing.
  • Health Industry Business Communications Council

    Health Industry Business Communications Council

    Health Industry Business Communications Council Registered Labelers: Accredited Auto-ID Labeling Standards Argentina New MedTek Devices Pty Ltd Oxavita SRL Norseld Pty Ltd. Novadien Healthcare Pty Ltd The following companies Odontit S.A. (and/or their subsidiaries/ PAMPAMED S.R.L. Numedico Technologies Pty Ltd divisions) have applied PATEJIM SRL Opto Global Pty. Ltd. for a Labeler Identification Orthocell Limited Code (LIC) assignment with Austria Prolotus Technologies Pty Ltd HIBCC*. By doing so, they afreeze GmbH Red Milawa Pty Ltd dba Magic Mobility have demonstrated their AMI GmbH SDI Limited commitment to patient safety Bender Medsystems GmbH Signostics Ltd. and logistical efficiency for BHS Technologies GmbH Sirtex Medical Pty Ltd their customers, the industry Metasys Medizintechnik GmbH Smith & Nephew Surgical Pty. Ltd. and the public at large. PAA Laboratories GmbH Staminalift International Limited Safersonic Medizinprodukte Handels The Pipette Company Pty. Ltd. Any organization that is GmbH Thermo Electron Corporation interested in using the HIBC W & H Dentalwerk Burmoos GmbH Vush Pty Ltd uniform labeling system may apply for the assignment of VUSH STIMULATION Australia one or more LICs. William A Cook Australia Pty. Ltd. Adv. Surgical Design & Manufacture, Ltd. Last updated 9-21-2021 AirPhysio Pty Ltd Belgium Annalise-AI Pty Ltd 3M Europe Apollo Medical Imaging Technology Pty Advanced Medical Diagnostics SA/NV Ltd Analis SA/NV Benra Pty Ltd dba Gelflex Laboratories Baxter World Trade Bioclone Australia Pty. Ltd. Bio-Rad RSL Candelis, Inc. Bio-Rad Lab Inc Clinical Diag. Group DePuy Australia Pty. Ltd. Biosource Europe SA For more information, please dorsaVi Ltd Cilag NV contact the HIBCC office at: EC Certification Service GmbH Coris Bioconcept Fink Engineering Pty Ltd Fuji Hunt Photographic Chemicals NV 2525 E.
  • List of Section 13F Securities

    List of Section 13F Securities

    List of Section 13F Securities 1st Quarter FY 2004 Copyright (c) 2004 American Bankers Association. CUSIP Numbers and descriptions are used with permission by Standard & Poors CUSIP Service Bureau, a division of The McGraw-Hill Companies, Inc. All rights reserved. No redistribution without permission from Standard & Poors CUSIP Service Bureau. Standard & Poors CUSIP Service Bureau does not guarantee the accuracy or completeness of the CUSIP Numbers and standard descriptions included herein and neither the American Bankers Association nor Standard & Poor's CUSIP Service Bureau shall be responsible for any errors, omissions or damages arising out of the use of such information. U.S. Securities and Exchange Commission OFFICIAL LIST OF SECTION 13(f) SECURITIES USER INFORMATION SHEET General This list of “Section 13(f) securities” as defined by Rule 13f-1(c) [17 CFR 240.13f-1(c)] is made available to the public pursuant to Section13 (f) (3) of the Securities Exchange Act of 1934 [15 USC 78m(f) (3)]. It is made available for use in the preparation of reports filed with the Securities and Exhange Commission pursuant to Rule 13f-1 [17 CFR 240.13f-1] under Section 13(f) of the Securities Exchange Act of 1934. An updated list is published on a quarterly basis. This list is current as of March 15, 2004, and may be relied on by institutional investment managers filing Form 13F reports for the calendar quarter ending March 31, 2004. Institutional investment managers should report holdings--number of shares and fair market value--as of the last day of the calendar quarter as required by Section 13(f)(1) and Rule 13f-1 thereunder.
  • Promotion and Development Collaborations Between Established Players

    Promotion and Development Collaborations Between Established Players

    Promotion and Development Collaborations Between Established Players Randall B. Sunberg Pharma and Biotech In-Licensing, Co-Development and Co-Promotion Agreements October 21-22, 2002 1 www.morganlewis.com MorganMorgan Lewis:Lewis: LifeLife SciencesSciences FocusFocus • Founded in 1873, today 1,100 lawyers in 13 offices worldwide • 175 Life Sciences professionals, including 90 with advanced degrees ranging from biochemistry to molecular genetics to immunology • Interdisciplinary coordination of transactions, IP, litigation, FDA and antitrust expertise to meet our clients’ strategic objectives • Recently ranked as the 5th leading transactional law firm in the nation by The American Lawyer "Corporate Scorecard” • Named by many Fortune 250 companies as one of their primary law firms • Recognized by corporate counsel for exceptional client service in a survey of Fortune 1000 companies • Featured prominently in the annual National Law Journal survey of “Who Defends Corporate America” 2 MorganMorgan Lewis:Lewis: RecentRecent LifeLife SciencesSciences DealsDeals • Aventis - Genta collaboration for co-development and commercialization of Genasense™ • Enzon - Elan acquisition of Abelcet® product rights and manufacturing assets • Quintiles - Eli Lilly co-promotion and marketing collaboration for Cymbalta™ • Adolor - GlaxoSmithKline development and commercialization collaboration for Alvimopan™ • Arena Pharmaceuticals - Merck drug discovery collaboration • Cephalon - Anesta stock-for-stock public company acquisition • Aventis - Millennium alliance
  • Active Labelers List Labeler ID Labeler Name Begin Date End Date 00002 ELI LILLY and COMPANY 01/01/1991 12/31/2078 00003 E.R

    Active Labelers List Labeler ID Labeler Name Begin Date End Date 00002 ELI LILLY and COMPANY 01/01/1991 12/31/2078 00003 E.R

    Kentucky Medicaid Pharmacy 3Q2011 Active Labelers List Labeler ID Labeler Name Begin Date End Date 00002 ELI LILLY AND COMPANY 01/01/1991 12/31/2078 00003 E.R. SQUIBB & SONS, INC. 01/01/1991 12/31/2078 00004 HOFFMANN-LA ROCHE 01/01/1991 12/31/2078 00005 LEDERLE LABORATORIES 01/01/1991 12/31/2078 00006 MERCK & CO., INC. 01/01/1991 12/31/2078 00007 GLAXOSMITHKLINE 01/01/1991 12/31/2078 00008 WYETH LABORATORIES 01/01/1991 12/31/2078 00009 PFIZER, INC 01/01/1991 12/31/2078 00013 PFIZER, INC. 01/01/1991 12/31/2078 00014 PFIZER, INC 01/01/1991 12/31/2078 00015 MEAD JOHNSON AND COMPANY 01/01/1991 12/31/2078 00023 ALLERGAN INC 01/01/1991 12/31/2078 00024 SANOFI-AVENTIS, US LLC 01/01/1991 12/31/2078 00025 PFIZER, INC. 01/01/1991 12/31/2078 00026 BAYER CORPORATION PHARMACEUTICAL DIV. 01/01/1991 12/31/2078 00028 NOVARTIS 01/01/1991 10/01/2011 00029 GLAXOSMITHKLINE 01/01/1991 12/31/2078 00031 A. H. ROBINS 01/01/1991 12/31/2078 00032 SOLVAY PHARMACEUTICALS, INC. 01/01/1991 12/31/2078 00037 MEDA PHARMACEUTICALS, INC. 01/01/1991 12/31/2078 00039 SANOFI-AVENTIS, US LLC 01/01/1991 12/31/2078 00045 ORTHO-MCNEIL-JANSSEN PHARMECEUTICAL, IN 01/01/1991 12/31/2078 00046 AYERST LABORATORIES 01/01/1991 12/31/2078 00049 PFIZER, INC 01/01/1991 12/31/2078 00051 UNIMED PHARMACEUTICALS, INC 10/01/1997 12/31/2078 00052 ORGANON USA INC.
  • PFIZER INC. (Exact Name of Registrant As Specified in Its Charter)

    PFIZER INC. (Exact Name of Registrant As Specified in Its Charter)

    UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 1-3619 PFIZER INC. (Exact name of registrant as specified in its charter) Delaware 13-5315170 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification Number) 235 East 42nd Street, New York, New York 10017 (Address of principal executive offices) (zip code) (212) 733-2323 (Registrant’s telephone number, including area code) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $.05 par value PFE New York Stock Exchange 0.000% Notes due 2020 PFE20A New York Stock Exchange 0.250% Notes due 2022 PFE22 New York Stock Exchange 1.000% Notes due 2027 PFE27 New York Stock Exchange Securities registered pursuant to Section 12(g) of the Act: None Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☒ No ☐ Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes ☐ No ☒ Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
  • Active Labelers Run Date : Feb 19, 2018

    Active Labelers Run Date : Feb 19, 2018

    Active Labelers Run Date : Feb 19, 2018 Labeler ID Labeler Name Contract Begin Date Contract End Date 00002 ELI LILLY AND COMPANY 01/01/1991 01/01/3000 00003 E.R. SQUIBB & SONS, LLC. 01/01/1991 01/01/3000 00004 HOFFMANN-LA ROCHE 01/01/1991 01/01/3000 00006 MERCK & CO., INC. 01/01/1991 01/01/3000 00007 GLAXOSMITHKLINE 01/01/1991 01/01/3000 00008 WYETH LABORATORIES 01/01/1991 01/01/3000 00009 PFIZER, INC 01/01/1991 01/01/3000 00013 PFIZER, INC. 01/01/1991 01/01/3000 00014 PFIZER, INC 01/01/1991 01/01/3000 00015 MEAD JOHNSON AND COMPANY 01/01/1991 01/01/3000 00023 ALLERGAN INC 01/01/1991 01/01/3000 00024 SANOFI-AVENTIS, US LLC 01/01/1991 01/01/3000 00025 PFIZER, INC. 01/01/1991 01/01/3000 00026 BAYER HEALTHCARE LLC 01/01/1991 01/01/3000 00029 GLAXOSMITHKLINE 01/01/1991 01/01/3000 00032 ABBVIE INC. 01/01/1991 01/01/3000 00037 MEDA PHARMACEUTICALS, INC. 01/01/1991 01/01/3000 00039 SANOFI-AVENTIS, US LLC 01/01/1991 01/01/3000 00046 AYERST LABORATORIES 01/01/1991 01/01/3000 00049 PFIZER, INC 01/01/1991 01/01/3000 00051 ABBVIE INC 10/01/1997 01/01/3000 00052 ORGANON USA INC. 01/01/1991 01/01/3000 00053 CSL BEHRING LLC 01/01/1991 01/01/3000 00054 WEST-WARD PHARMACEUTICALS CORP. 01/01/1991 01/01/3000 00056 BRISTOL-MYERS SQUIBB PHARMA CO. 01/01/1991 01/01/3000 00062 ORTHO MCNEIL PHARMACEUTICALS 01/01/1991 01/01/3000 00064 HEALTHPOINT, LTD.
  • The Bottom 99

    The Bottom 99

    The Top 100 June 1, 2004 A list of stocks topping our custom 'torpedo’ screen. Updated monthly. ABFI AMER BUSINESS FINL SVCS INC Financials ABGX ABGENIX INC Health Care ADLR ADOLOR CORP Health Care AGEN ANTIGENICS INC/DEL Health Care AGI ALLIANCE GAMING CORP Consumer Cyclicals AKLM ACCLAIM ENMNT INC Technology ALKS ALKERMES INC Health Care ALXN ALEXION PHARMACEUTICALS INC Health Care AMLN AMYLIN PHARMACEUTICALS INC Health Care APHT APHTON CORP Health Care ARNA ARENA PHARMACEUTICALS INC Health Care BIOV BIOVERIS CORP Health Care BMRN BIOMARIN PHARMACEUTICAL INC Health Care BVSN BROADVISION INC Technology CBRX COLUMBIA LABORATORIES INC Health Care CCRD CONCORD COMMUNICATIONS INC Technology CDE COEUR D'ALENE MINES CORP Basic Materials CFFN CAPITOL FEDERAL FINANCIAL Financials COMS 3COM CORP Technology CPN CALPINE CORP Utilities CRAY CRAY INC Technology CRGN CURAGEN CORP Health Care CRXA CORIXA CORP Health Care CYBX CYBERONICS INC Health Care DAL DELTA AIR LINES INC Capital Goods DEPO DEPOMED INC Health Care DMX I-TRAX INC Health Care DRXR DREXLER TECHNOLOGY CORP Technology DSCO DISCOVERY LABORATORIES INC Health Care DV DEVRY INC Capital Goods ELGX ENDOLOGIX INC Health Care EPIX EPIX MEDICAL INC Health Care EXEL EXELIXIS INC Health Care EXLT EXULT INC Capital Goods FCP FALCON PRODUCTS INC Capital Goods FMKT FREEMARKETS INC Technology FXEN FX ENERGY INC Energy GBTVK GRANITE BROADCASTING Consumer Cyclicals GENE OSCIENT PHARMACEUTICALS CORP Health Care GGNS GENUS INC Technology GLFD GUILFORD PHARMACEUTICAL INC Health Care GMRK GULFMARK OFFSHORE
  • Rebateable Manufacturers

    Rebateable Manufacturers

    Rebateable Labelers – July 2021 Manufacturers are responsible for updating their eligible drugs and pricing with CMS. Montana Healthcare Programs will not pay for an NDC not updated with CMS. Note: Some manufacturers on this list may have some NDCs that are covered and others that are not. Manufacturer ID Manufacturer Name 00002 ELI LILLY AND COMPANY 00003 E.R. SQUIBB & SONS, LLC. 00004 HOFFMANN-LA ROCHE 00006 MERCK & CO., INC. 00007 GLAXOSMITHKLINE 00008 WYETH PHARMACEUTICALS LLC, 00009 PHARMACIA AND UPJOHN COMPANY LLC 00013 PFIZER LABORATORIES DIV PFIZER INC 00015 MEAD JOHNSON AND COMPANY 00023 ALLERGAN INC 00024 SANOFI-AVENTIS, US LLC 00025 PFIZER LABORATORIES DIV PFIZER INC 00026 BAYER HEALTHCARE LLC 00032 ABBVIE INC. 00037 MEDA PHARMACEUTICALS, INC. 00039 SANOFI-AVENTIS, US LLC 00046 WYETH PHARMACEUTICALS INC. 00049 ROERIG 00051 ABBVIE INC 00052 ORGANON USA INC. 00053 CSL BEHRING L.L.C. 00054 HIKMA PHARMACEUTICAL USA, INC. 00056 BRISTOL-MYERS SQUIBB PHARMA CO. 00065 ALCON LABORATORIES, INC. 00068 AVENTIS PHARMACEUTICALS 00069 PFIZER LABORATORIES DIV PFIZER INC 00071 PARKE-DAVIS DIV OF PFIZER 00074 ABBVIE INC 00075 AVENTIS PHARMACEUTICALS, INC. 00078 NOVARTIS 00085 SCHERING CORPORATION 00087 BRISTOL-MYERS SQUIBB COMPANY 00088 AVENTIS PHARMACEUTICALS 00093 TEVA PHARMACEUTICALS USA, INC. 00095 BAUSCH HEALTH US, LLC Page 1 of 19 Manufacturer ID Manufacturer Name 00096 PERSON & COVEY, INC. 00113 L. PERRIGO COMPANY 00115 IMPAX GENERICS 00116 XTTRIUM LABORATORIES, INC. 00121 PHARMACEUTICAL ASSOCIATES, INC. 00131 UCB, INC. 00132 C B FLEET COMPANY INC 00143 HIKMA PHARMACEUTICAL USA, INC. 00145 STIEFEL LABORATORIES, INC, 00168 E FOUGERA AND CO. 00169 NOVO NORDISK, INC. 00172 TEVA PHARMACEUTICALS USA, INC 00173 GLAXOSMITHKLINE 00178 MISSION PHARMACAL COMPANY 00185 EON LABS, INC.